{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T08:41:28Z","timestamp":1778056888386,"version":"3.51.4"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T00:00:00Z","timestamp":1728432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T00:00:00Z","timestamp":1728432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100021856","name":"Ministero dell'Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["PE0000006"],"award-info":[{"award-number":["PE0000006"]}],"id":[{"id":"10.13039\/501100021856","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004434","name":"Universit\u00e0 degli Studi di Firenze","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004434","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s40263-024-01125-9","type":"journal-article","created":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T15:14:11Z","timestamp":1728486851000},"page":"961-971","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy of Cariprazine in the Psychosis Spectrum: A Systematic Review and Network Meta-Analysis of Randomised Controlled Trials in Schizophrenia and Bipolar Disorder"],"prefix":"10.1007","volume":"38","author":[{"given":"Livio","family":"Tarchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Bugini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristiano","family":"Dani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuele","family":"Cassioli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleonora","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Lucarelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valdo","family":"Ricca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saverio","family":"Caini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1265-491X","authenticated-orcid":false,"given":"Giovanni","family":"Castellini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,10,9]]},"reference":[{"key":"1125_CR1","unstructured":"Vraylar (cariprazine). Silver Spring; 2015 Sep. Report No.: 3821760. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2015\/204370Orig1Orig2s000Approv.pdf. Accessed 22 Aug 2024."},{"key":"1125_CR2","unstructured":"European Medical Agency. Reagila: EPAR\u2014Summary for the public. 2017. Report No.: EMA\/339882\/2017. https:\/\/www.ema.europa.eu\/en\/documents\/overview\/reagila-epar-summary-public_en.pdf. Accessed 22 Aug 2024."},{"key":"1125_CR3","unstructured":"Vraylar (cariprazine). Silver Spring; 2022 Dec. Report No.: 5095981. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/204370s009lbl.pdf. Accessed 22 Aug 2024."},{"key":"1125_CR4","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1097\/YIC.0000000000000189","volume":"32","author":"F Corponi","year":"2017","unstructured":"Corponi F, Serretti A, Montgomery S, Fabbri C. Cariprazine specificity profile in the treatment of acute schizophrenia: a meta-analysis and meta-regression of randomized-controlled trials. Int Clin Psychopharmacol. 2017;32:309\u201318.","journal-title":"Int Clin Psychopharmacol"},{"key":"1125_CR5","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1097\/JCP.0000000000000834","volume":"38","author":"M-J Zhao","year":"2018","unstructured":"Zhao M-J, Qin B, Wang J-B, Zhang Y-P, Zhao J-T, Mao Y-G, et al. Efficacy and acceptability of Cariprazine in acute exacerbation of schizophrenia: meta-analysis of randomized placebo-controlled trials. J Clin Psychopharmacol. 2018;38:55\u20139.","journal-title":"J Clin Psychopharmacol"},{"key":"1125_CR6","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.schres.2024.04.016","volume":"269","author":"Y Wang","year":"2024","unstructured":"Wang Y, Xu Y, Wu P, Zhou Y, Zhang H, Li Z, et al. Exploring the interplay between core and mood symptoms in schizophrenia: a network analysis. Schizophr Res. 2024;269:28\u201335.","journal-title":"Schizophr Res"},{"key":"1125_CR7","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/S2215-0366(15)00112-1","volume":"2","author":"B Pavlova","year":"2015","unstructured":"Pavlova B, Perlis RH, Alda M, Uher R. Lifetime prevalence of anxiety disorders in people with bipolar disorder: a systematic review and meta-analysis. Lancet Psychiatry. 2015;2:710\u20137.","journal-title":"Lancet Psychiatry"},{"key":"1125_CR8","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1111\/bdi.12850","volume":"22","author":"JV Pinto","year":"2020","unstructured":"Pinto JV, Saraf G, Vigo D, Keramatian K, Chakrabarty T, Yatham LN. Cariprazine in the treatment of bipolar disorder: a systematic review and meta-analysis. Bipolar Disord. 2020;22:360\u201371.","journal-title":"Bipolar Disord"},{"key":"1125_CR9","doi-asserted-by":"publisher","first-page":"36","DOI":"10.24869\/psyd.2020.36","volume":"32","author":"H Cooper","year":"2020","unstructured":"Cooper H, Mishriky R, Reyad AA. Efficacy and safety of cariprazine in acute management of psychiatric disorders: a meta-analysis of randomized controlled trials. Psychiatr Danub. 2020;32:36\u201345.","journal-title":"Psychiatr Danub"},{"key":"1125_CR10","volume-title":"The oxford handbook of phenomenological psychopathology","year":"2019","unstructured":"Stanghellini G, Broome M, Fernandez AV, Fusar-Poli P, Raballo A, Rosfort R, et al editors. The oxford handbook of phenomenological psychopathology. Oxford: Oxford University Press; 2019."},{"key":"1125_CR11","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1007\/s40473-015-0040-7","volume":"2","author":"P DeRosse","year":"2015","unstructured":"DeRosse P, Karlsgodt KH. Examining the psychosis continuum. Curr Behav Neurosci Rep. 2015;2:80\u20139.","journal-title":"Curr Behav Neurosci Rep"},{"key":"1125_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2024.1378439","author":"GP Merola","year":"2024","unstructured":"Merola GP, Tarchi L, Saccaro LF, Delavari F, Piguet C, Van De Ville D, et al. Transdiagnostic markers across the psychosis continuum: a systematic review and meta-analysis of resting state fMRI studies. Front Psychiatry. 2024. https:\/\/doi.org\/10.3389\/fpsyt.2024.1378439.","journal-title":"Front Psychiatry"},{"key":"1125_CR13","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.schres.2014.08.010","volume":"159","author":"A Consoli","year":"2014","unstructured":"Consoli A, Brunelle J, Bodeau N, Lou\u00ebt E, Deniau E, Perisse D, et al. Diagnostic transition towards schizophrenia in adolescents with severe bipolar disorder type I: an 8-year follow-up study. Schizophr Res. 2014;159:284\u201391.","journal-title":"Schizophr Res"},{"key":"1125_CR14","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1093\/schbul\/sbu016","volume":"40","author":"AG Cardno","year":"2014","unstructured":"Cardno AG, Owen MJ. Genetic relationships between schizophrenia, bipolar disorder, and schizoaffective disorder. Schizophr Bull. 2014;40:504\u201315.","journal-title":"Schizophr Bull"},{"key":"1125_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2023.1136097","author":"HM Ihler","year":"2023","unstructured":"Ihler HM, Lyngstad SH, M\u00f8rch-Johnsen LE, Lagerberg TV, Melle I, Romm KL. A transdiagnostic approach to negative symptoms: exploring factor structure and negative symptoms in bipolar disorders. Front Psychiatry. 2023. https:\/\/doi.org\/10.3389\/fpsyt.2023.1136097.","journal-title":"Front Psychiatry"},{"key":"1125_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372: n71.","journal-title":"BMJ"},{"key":"1125_CR17","first-page":"143","volume-title":"Choosing effect measures and computing estimates of effect. Cochrane Handb Syst Rev Interv","author":"JP Higgins","year":"2019","unstructured":"Higgins JP, Li T, Deeks JJ. Choosing effect measures and computing estimates of effect. Cochrane Handb Syst Rev Interv. New York: Wiley; 2019. p. 143\u201376."},{"key":"1125_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366: l4898.","journal-title":"BMJ"},{"key":"1125_CR19","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.3758\/s13428-020-01373-9","volume":"52","author":"B Fern\u00e1ndez-Castilla","year":"2020","unstructured":"Fern\u00e1ndez-Castilla B, Jamshidi L, Declercq L, Beretvas SN, Onghena P, Van den Noortgate W. The application of meta-analytic (multi-level) models with multiple random effects: a systematic review. Behav Res Methods. 2020;52:2031\u201352.","journal-title":"Behav Res Methods"},{"key":"1125_CR20","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1177\/1094428119857471","volume":"24","author":"J Gooty","year":"2021","unstructured":"Gooty J, Banks GC, Loignon AC, Tonidandel S, Williams CE. Meta-analyses as a multi-level model. Organ Res Methods. 2021;24:389\u2013411.","journal-title":"Organ Res Methods"},{"key":"1125_CR21","doi-asserted-by":"publisher","first-page":"576","DOI":"10.3758\/s13428-012-0261-6","volume":"45","author":"W Van den Noortgate","year":"2013","unstructured":"Van den Noortgate W, L\u00f3pez-L\u00f3pez JA, Mar\u00edn-Mart\u00ednez F, S\u00e1nchez-Meca J. Three-level meta-analysis of dependent effect sizes. Behav Res Methods. 2013;45:576\u201394.","journal-title":"Behav Res Methods"},{"key":"1125_CR22","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JPT Higgins","year":"2003","unstructured":"Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557\u201360.","journal-title":"BMJ"},{"key":"1125_CR23","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.jclinepi.2010.08.002","volume":"64","author":"RD Riley","year":"2011","unstructured":"Riley RD, Gates S, Neilson J, Alfirevic Z. Statistical methods can be improved within Cochrane pregnancy and childbirth reviews. J Clin Epidemiol. 2011;64:608\u201318.","journal-title":"J Clin Epidemiol"},{"key":"1125_CR24","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629\u201334.","journal-title":"BMJ"},{"key":"1125_CR25","first-page":"285","volume-title":"Undertaking network meta-analyses. Cochrane Handb Syst Rev Interv","author":"A Chaimani","year":"2019","unstructured":"Chaimani A, Caldwell DM, Li T, Higgins JP, Salanti G. Undertaking network meta-analyses. Cochrane Handb Syst Rev Interv. New York: Wiley; 2019. p. 285\u2013320."},{"key":"1125_CR26","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1002\/jrsm.1270","volume":"8","author":"G R\u00fccker","year":"2017","unstructured":"R\u00fccker G, Schwarzer G. Resolve conflicting rankings of outcomes in network meta-analysis: partial ordering of treatments. Res Synth Methods. 2017;8:526\u201336.","journal-title":"Res Synth Methods."},{"key":"1125_CR27","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","volume":"64","author":"G Salanti","year":"2011","unstructured":"Salanti G, Ades AE, Ioannidis JPA. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol. 2011;64:163\u201371.","journal-title":"J Clin Epidemiol"},{"key":"1125_CR28","unstructured":"R Core Team. R: A language and environment for statistical computing. Vienna, Austria; 2024. https:\/\/www.R-project.org."},{"key":"1125_CR29","unstructured":"RStudio Team. RStudio: Integrated Development for R. Boston, MA: RStudio, PBC; 2024. http:\/\/www.rstudio.com\/."},{"key":"1125_CR30","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","volume":"22","author":"S Balduzzi","year":"2019","unstructured":"Balduzzi S, R\u00fccker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health. 2019;22:153\u201360.","journal-title":"Evid Based Ment Health"},{"key":"1125_CR31","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v106.i02","author":"S Balduzzi","year":"2023","unstructured":"Balduzzi S, R\u00fccker G, Nikolakopoulou A, Papakonstantinou T, Salanti G, Efthimiou O, et al. netmeta: an R package for network meta-analysis using frequentist methods. J Stat Softw. 2023. https:\/\/doi.org\/10.18637\/jss.v106.i02.","journal-title":"J Stat Softw"},{"key":"1125_CR32","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v036.i03","author":"W Viechtbauer","year":"2010","unstructured":"Viechtbauer W. Conducting meta-analyses in R with the metafor package. J Stat Softw. 2010. https:\/\/doi.org\/10.18637\/jss.v036.i03.","journal-title":"J Stat Softw"},{"key":"1125_CR33","doi-asserted-by":"publisher","DOI":"10.1002\/cl2.1230","volume":"18","author":"NR Haddaway","year":"2022","unstructured":"Haddaway NR, Page MJ, Pritchard CC, McGuinness LA. PRISMA2020: an R package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and Open Synthesis. Campbell Syst Rev. 2022;18: e1230.","journal-title":"Campbell Syst Rev"},{"key":"1125_CR34","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.21105\/joss.01686","volume":"4","author":"H Wickham","year":"2019","unstructured":"Wickham H, Averick M, Bryan J, Chang W, McGowan LD, Fran\u00e7ois R, et al. Welcome to the tidyverse. J Open Sour Softw. 2019;4:1686.","journal-title":"J Open Sour Softw"},{"key":"1125_CR35","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1111\/bdi.12852","volume":"22","author":"WR Earley","year":"2020","unstructured":"Earley WR, Burgess MV, Khan B, Rekeda L, Suppes T, Tohen M, et al. Efficacy and safety of cariprazine in bipolar I depression: a double-blind, placebo-controlled phase 3 study. Bipolar Disord. 2020;22:372\u201384.","journal-title":"Bipolar Disord"},{"key":"1125_CR36","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.jad.2019.11.098","volume":"263","author":"WR Earley","year":"2020","unstructured":"Earley WR, Burgess M, Rekeda L, Hankinson A, McIntyre RS, Suppes T, et al. A pooled post hoc analysis evaluating the safety and tolerability of cariprazine in bipolar depression. J Affect Disord. 2020;263:386\u201395.","journal-title":"J Affect Disord"},{"key":"1125_CR37","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1176\/appi.ajp.2018.18070824","volume":"176","author":"W Earley","year":"2019","unstructured":"Earley W, Burgess MV, Rekeda L, Dickinson R, Szatm\u00e1ri B, N\u00e9meth G, et al. Cariprazine treatment of bipolar depression: a randomized double-blind placebo-controlled phase 3 study. Am J Psychiatry. 2019;176:439\u201348.","journal-title":"Am J Psychiatry"},{"key":"1125_CR38","doi-asserted-by":"publisher","first-page":"e1574","DOI":"10.4088\/JCP.15m09997","volume":"76","author":"S Durgam","year":"2015","unstructured":"Durgam S, Cutler AJ, Lu K, Migliore R, Ruth A, Laszlovszky I, et al. Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, phase 3, randomized, double-blind, placebo- and active-controlled trial. J Clin Psychiatry. 2015;76:e1574-1582.","journal-title":"J Clin Psychiatry"},{"key":"1125_CR39","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/bdi.12238","volume":"17","author":"S Durgam","year":"2015","unstructured":"Durgam S, Starace A, Li D, Migliore R, Ruth A, N\u00e9meth G, et al. The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial. Bipolar Disord. 2015;17:63\u201375.","journal-title":"Bipolar Disord"},{"key":"1125_CR40","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1097\/JCP.0000000000000346","volume":"35","author":"JM Kane","year":"2015","unstructured":"Kane JM, Zukin S, Wang Y, Lu K, Ruth A, Nagy K, et al. Efficacy and safety of cariprazine in acute exacerbation of schizophrenia: results from an international, phase III clinical trial. J Clin Psychopharmacol. 2015;35:367.","journal-title":"J Clin Psychopharmacol"},{"key":"1125_CR41","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.schres.2013.11.041","volume":"152","author":"S Durgam","year":"2014","unstructured":"Durgam S, Starace A, Li D, Migliore R, Ruth A, N\u00e9meth G, et al. An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial. Schizophr Res. 2014;152:450\u20137.","journal-title":"Schizophr Res"},{"key":"1125_CR42","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.jad.2014.11.018","volume":"174","author":"GS Sachs","year":"2015","unstructured":"Sachs GS, Greenberg WM, Starace A, Lu K, Ruth A, Laszlovszky I, et al. Cariprazine in the treatment of acute mania in bipolar I disorder: a double-blind, placebo-controlled, Phase III trial. J Affect Disord. 2015;174:296\u2013302.","journal-title":"J Affect Disord"},{"key":"1125_CR43","doi-asserted-by":"publisher","first-page":"284","DOI":"10.4088\/JCP.14m09081","volume":"76","author":"JR Calabrese","year":"2015","unstructured":"Calabrese JR, Keck PE, Starace A, Lu K, Ruth A, Laszlovszky I, et al. Efficacy and safety of low- and high-dose cariprazine in acute and mixed mania associated with bipolar I disorder: a double-blind, placebo-controlled study. J Clin Psychiatry. 2015;76:284\u201392.","journal-title":"J Clin Psychiatry"},{"key":"1125_CR44","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1176\/appi.ajp.2015.15020164","volume":"173","author":"S Durgam","year":"2016","unstructured":"Durgam S, Earley W, Lipschitz A, Guo H, Laszlovszky I, N\u00e9meth G, et al. An 8-week randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of cariprazine in patients with bipolar I depression. Am J Psychiatry. 2016;173:271\u201381.","journal-title":"Am J Psychiatry"},{"key":"1125_CR45","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1097\/YIC.0000000000000187","volume":"32","author":"W Earley","year":"2017","unstructured":"Earley W, Durgam S, Lu K, Laszlovszky I, Debelle M, Kane JM. Safety and tolerability of cariprazine in patients with acute exacerbation of schizophrenia: a pooled analysis of four phase II\/III randomized, double-blind, placebo-controlled studies. Int Clin Psychopharmacol. 2017;32:319\u201328.","journal-title":"Int Clin Psychopharmacol"},{"key":"1125_CR46","doi-asserted-by":"publisher","first-page":"327","DOI":"10.2147\/DDDT.S95100","volume":"10","author":"T Nakamura","year":"2016","unstructured":"Nakamura T, Kubota T, Iwakaji A, Imada M, Kap\u00e1s M, Morio Y. Clinical pharmacology study of cariprazine (MP-214) in patients with schizophrenia (12-week treatment). Drug Des Dev Ther. 2016;10:327\u201338.","journal-title":"Drug Des Dev Ther"},{"key":"1125_CR47","doi-asserted-by":"crossref","unstructured":"Stahl SM. Stahl\u2019s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 5\u00b0 edizione. Cambridge: Cambridge University Press; 2021.","DOI":"10.1017\/9781108975292"},{"key":"1125_CR48","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","volume":"394","author":"M Huhn","year":"2019","unstructured":"Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394:939\u201351.","journal-title":"Lancet"},{"key":"1125_CR49","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: Fifth Edition Text Revision DSM-5-TRTM. American Psychiatric Association Publishing; 2022.","DOI":"10.1176\/appi.books.9780890425787"},{"key":"1125_CR50","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41537-020-00111-6","volume":"6","author":"E van Dellen","year":"2020","unstructured":"van Dellen E, B\u00f6rner C, Schutte M, van Montfort S, Abramovic L, Boks MP, et al. Functional brain networks in the schizophrenia spectrum and bipolar disorder with psychosis. NPJ Schizophr. 2020;6:22.","journal-title":"NPJ Schizophr"},{"key":"1125_CR51","doi-asserted-by":"publisher","first-page":"4314","DOI":"10.1038\/s41467-022-31873-5","volume":"13","author":"TS Wingo","year":"2022","unstructured":"Wingo TS, Liu Y, Gerasimov ES, Vattathil SM, Wynne ME, Liu J, et al. Shared mechanisms across the major psychiatric and neurodegenerative diseases. Nat Commun. 2022;13:4314.","journal-title":"Nat Commun"},{"key":"1125_CR52","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1016\/j.cell.2019.11.020","volume":"179","author":"Cross-Disorder Group of the Psychiatric Genomics Consortium","year":"2019","unstructured":"Cross-Disorder Group of the Psychiatric Genomics Consortium. Genomic relationships, novel loci, and pleiotropic mechanisms across eight psychiatric disorders. Cell. 2019;179:1469\u201382 (e11).","journal-title":"Cell"}],"updated-by":[{"DOI":"10.1007\/s40263-024-01146-4","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T00:00:00Z","timestamp":1733961600000}}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-024-01125-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-024-01125-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-024-01125-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T08:15:24Z","timestamp":1734077724000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-024-01125-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,9]]},"references-count":52,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["1125"],"URL":"https:\/\/doi.org\/10.1007\/s40263-024-01125-9","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40263-024-01146-4","asserted-by":"object"}]},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,9]]},"assertion":[{"value":"3 September 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2024","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original article has been corrected. Author Eleonora Rossi's affiliation tagged correctly in XML.","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2024","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40263-024-01146-4","URL":"https:\/\/doi.org\/10.1007\/s40263-024-01146-4","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open access funding provided by Universit\u00e0 degli Studi di Firenze within the CRUI-CARE Agreement. Work supported by #NEXTGENERATIONEU (NGEU) and funded by the Ministry of University and Research (MUR), National Recovery and Resilience Plan (NRRP), project MNESYS (PE0000006)\u2014a multiscale integrated approach to the study of the nervous system in health and disease (DN. 1553\u2014DN. 11.10.2022). Funding included expenses related to personnel. No influence on research results was exerted by the funding agency. Open access funding provided by Universit\u00e0 degli Studi di Firenze within the CRUI-CARE Agreement.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors declare that they have no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The database of the studies, with the extracted data items, can be shared upon reasonable request to the corresponding author.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"The code supporting the present work can be shared upon reasonable request to the corresponding author.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"L.T.: Conceptualization, methodology, software, formal analysis, investigation, data curation, writing\u2014original draft, writing\u2014review and editing and visualization. S.B.: Conceptualization, methodology, investigation, data curation, writing\u2014original draft preparation and writing\u2014review and editing. C.D.: Conceptualization, methodology, investigation, data curation, writing\u2014original draft preparation and writing\u2014review and editing. E.C.: Conceptualization, methodology, investigation, writing\u2014original draft preparation, writing\u2014review and editing and supervision. E.R.: Conceptualization, methodology, investigation, writing\u2014original draft preparation, writing\u2014review and editing and supervision. S.L.: Conceptualization, investigation, writing\u2014review and editing and supervision. V.R.: Conceptualization, investigation, writing\u2014review and editing, supervision and project administration. S.C.: Conceptualization, methodology, data curation, investigation, writing\u2014original draft preparation, writing\u2014review and editing and supervision. G.C.: Conceptualization, methodology, investigation, writing\u2014original draft preparation, writing\u2014review and editing, supervision and project administration. All authors have read and approved the final submitted manuscript and agree to be accountable for the work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors contributions"}}]}}